On December 31, 2017, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:


	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
		(Euro, in thousands)
Operating lease obligations	€	26,346	€	4,150	€	7,820	€	6,010	€	8,366
Purchase commitments		65,246		53,010		11,233		1,002		—
Total contractual obligations & commitments	€	91,592	€	57,160	€	19,053	€	7,012	€	8,366

On December 31, 2016, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:


	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
		(Euro, in thousands)
Operating lease obligations	€	27,263	€	4,114	€	6,494	€	5,504	€	11,151
Purchase commitments		27,579		27,084		495		—		—
Total contractual obligations & commitments	€	54,842	€	31,198	€	6,989	€	5,504	€	11,151

In addition to the tables above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounts to €129.0 million at December 31, 2017 (€199.0 million at December 31, 2016), for which we have direct purchase commitments of €10.1 million at December 31, 2017 (€2.0 million at December 31, 2016) reflected in the tables above.

On December 31, 2015, we had outstanding obligations for future minimum rent payments and purchase commitments, which become due as follows:


	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
		(Euro, in thousands)
Operating lease obligations	€	31,210	€	4,002	€	7,253	€	5,683	€	14,273
Purchase commitments		20,079		17,898		2,180		—		—
Total contractual obligations & commitments	€	51,289	€	21,900	€	9,433	€	5,683	€	14,273